Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw.

We describe a case of a 64-year-old female diagnosed with multiple myeloma in 2001. She was treated with pamidronate and subsequently zolodronic acid before developing spontaneous bisphosphonate related osteonecrosis (BRONJ) of the left maxilla in December 2008. Over the next two years the BRONJ was treated conservatively but gradually became more symptomatic. About three years after her last dose of zolodronic acid with her symptoms increasing, she underwent radical surgical excision of all diseased bone and flap reconstruction. The patient is now six months postoperative and symptom free.

[1]  F. Spijkervet,et al.  A systematic review of bisphosphonate osteonecrosis (BON) in cancer , 2010, Supportive Care in Cancer.

[2]  R. Williamson,et al.  Surgical management of bisphosphonate induced osteonecrosis of the jaws. , 2010, International journal of oral and maxillofacial surgery.

[3]  E. Nkenke,et al.  Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up , 2010, Supportive Care in Cancer.

[4]  A. Goss,et al.  Alveolar bone and the bisphosphonates. , 2009, Australian dental journal.

[5]  T. Hughes,et al.  Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[6]  A. Zannettino,et al.  Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment , 2009, Internal medicine journal.

[7]  R. Moon,et al.  Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[8]  A. Goss,et al.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[9]  E. Carlson,et al.  Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[10]  L. Elting,et al.  Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. , 2006, The Lancet. Oncology.

[11]  D. Samson,et al.  Guidelines on the diagnosis and management of multiple myeloma 2005 , 2006, British journal of haematology.

[12]  N. Fazzalari,et al.  The dental implications of bisphosphonates and bone disease. , 2005, Australian dental journal.

[13]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Epstein,et al.  Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. , 2005, Journal of the American Dental Association.

[15]  C. Migliorati.  Bisphosphanates and oral cavity avascular bone necrosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Pogrel,et al.  Osteonecrosis of the jaws associated with cancer chemotherapy. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[17]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.